ROIV - Roivant Sciences Ltd.

28.78
-0.940   -3.266%

Share volume: 5,686,422
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$29.72
-0.94
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 23%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.34%
1 Month
4.01%
3 Months
37.11%
6 Months
122.93%
1 Year
172.02%
2 Year
169.48%
Key data
Stock price
$28.78
P/E Ratio 
0.00
DAY RANGE
$28.31 - $29.38
EPS 
-$0.61
52 WEEK RANGE
$8.73 - $30.03
52 WEEK CHANGE
$172.02
MARKET CAP 
15.092 B
YIELD 
N/A
SHARES OUTSTANDING 
715.701 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,040,329
AVERAGE 30 VOLUME 
$7,493,808
Company detail
CEO: Matthew Gline
Region: US
Website: roivant.com
Employees: 860
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom.

Recent news